{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:52Z","timestamp":1781643292294,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Olaparib, the first clinically approved poly (ADP-ribose) polymerase (PARP) inhibitor, may be repurposed for non-oncological conditions such as acute respiratory distress syndrome (ARDS), where PARP-1 inhibition has shown benefits in preclinical models. We investigated the expression and functional status of PARP-1 and the effects of olaparib in peripheral blood mononuclear cells (PBMCs) from ARDS patients and healthy controls. PBMCs from healthy volunteers (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20098) and ARDS patients (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20098) were isolated via Ficoll gradient. PARP-1, cleaved PARP (cPARP), and PAR polymers were assessed by Western blotting. Cytokine production was measured in plasma and in PBMC supernatants after 1\u00a0h preincubation with olaparib (10\u00a0\u00b5M) or vehicle, followed by LPS (100\u00a0ng\/ml) stimulation for 4\u00a0h. Cellular bioenergetics were analyzed using Seahorse XFe24 after H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    (100\u00a0\u00b5M, 2\u00a0h) with or without olaparib pretreatment. Control PBMCs showed a lymphocyte-predominant population with mostly full-length PARP-1. In ARDS Day 1 samples, PARylated proteins increased and PARP became downregulated. By Day 8, PARylation decreased and full-length PARP-1, as well as cleaved PARP-1 were detectable. Olaparib treatment of the cells did not alter the LPS-induced cytokine responses. Exposure of healthy PBMCs to oxidative stress suppressed cellular bioenergetics, and this effect was attenuated by olaparib. However, in ARDS PBMCs, which were already bioenergetically suppressed, oxidative stress had no further effect, and olaparib was without protective effect. Thus, in PBMCs isolated from ARDS, olaparib\u2019s cytoprotective effect is no longer detectable, likely due to PARP-1 inactivation and degradation.\n                  <\/jats:p>","DOI":"10.1186\/s12931-026-03623-4","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:07:10Z","timestamp":1773673630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cleavage and inactivation of poly(ADP-ribose) polymerase in peripheral blood mononuclear cells of patients with acute respiratory distress syndrome"],"prefix":"10.1186","volume":"27","author":[{"given":"Sidn\u00e9ia Sousa","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Ascen\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Zuhra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Gianini Figueiredo","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"de Oliveira Cavalcanti Peres Rodrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackeline Y.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena Karina Colo","family":"Brunialti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Pecze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Liaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Salom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"3623_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/SHK.0000000000001402","volume":"53","author":"A Ahmad","year":"2020","unstructured":"Ahmad A, Haas De Mello A, Szczesny B, T\u00f6r\u00f6 G, Marcatti M, Druzhyna N, et al. Effects of the poly(ADP-ribose) polymerase inhibitor olaparib in cerulein-induced pancreatitis. Shock. 2020;53:653\u201365.","journal-title":"Shock"},{"key":"3623_CR2","doi-asserted-by":"publisher","first-page":"104263","DOI":"10.1016\/j.phrs.2019.104263","volume":"145","author":"A Ahmad","year":"2019","unstructured":"Ahmad A, Vieira JC, de Mello AH, de Lima TM, Ariga SK, Barbeiro DF, et al. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: a potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis. Pharmacol Res. 2019;145:104263.","journal-title":"Pharmacol Res"},{"key":"3623_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-025-01982-5","volume":"13","author":"PN Akkaya","year":"2025","unstructured":"Akkaya PN, Miranda M, Almansa I, Elmas C, Trifunovic D, Hosseinzadeh Z, et al. PARP inhibition preserves cone photoreceptors in rd2 retina. Acta Neuropathol Commun. 2025;13:68.","journal-title":"Acta Neuropathol Commun"},{"key":"3623_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bph.13748","volume":"175","author":"NA Berger","year":"2018","unstructured":"Berger NA, Besson VC, Boulares AH, B\u00fcrkle A, Chiarugi A, Clark RS, et al. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol. 2018;175:192\u2013222.","journal-title":"Br J Pharmacol"},{"key":"3623_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1042\/bj3080131","volume":"308","author":"M Bhatia","year":"1995","unstructured":"Bhatia M, Kirkland JB, Meckling-Gill KA. Modulation of poly(ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells. Biochem J. 1995;308:131\u20137.","journal-title":"Biochem J"},{"key":"3623_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(22)01485-4","volume":"400","author":"LDJ Bos","year":"2022","unstructured":"Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400:1145\u201356.","journal-title":"Lancet"},{"key":"3623_CR7","doi-asserted-by":"publisher","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","volume":"274","author":"AH Boulares","year":"1999","unstructured":"Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999;274:22932\u201340.","journal-title":"J Biol Chem"},{"key":"3623_CR8","doi-asserted-by":"publisher","first-page":"e0036421","DOI":"10.1128\/Spectrum.00364-21","volume":"9","author":"S Choudhuri","year":"2021","unstructured":"Choudhuri S, Bhavnani SK, Zhang W, Botelli V, Barrientos N, I\u00f1iguez F, et al. Prognostic performance of peripheral blood biomarkers in identifying seropositive individuals at risk of developing clinically symptomatic Chagas cardiomyopathy. Microbiol Spectr. 2021;9:e0036421.","journal-title":"Microbiol Spectr"},{"key":"3623_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19:711\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"3623_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.radonc.2017.10.017","volume":"126","author":"R de Haan","year":"2018","unstructured":"de Haan R, Pluim D, van Triest B, van den Heuvel M, Peulen H, van Berlo D, et al. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials. Radiother Oncol. 2018;126:443\u20139.","journal-title":"Radiother Oncol"},{"key":"3623_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4049\/immunohorizons.2400058","volume":"8","author":"LJ Delinois","year":"2024","unstructured":"Delinois LJ, Sharma A, Ramesh AK, Boatright LD, Li Q, Xu R, et al. Poly(ADP-ribose) polymerase-1 regulates pyroptosis independent function of NLRP3 inflammasome in neutrophil extracellular trap formation. Immunohorizons. 2024;8:586\u201397.","journal-title":"Immunohorizons"},{"key":"3623_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1042\/CS20150122","volume":"129","author":"MA Ghonim","year":"2015","unstructured":"Ghonim MA, Pyakurel K, Ibba SV, Wang J, Rodriguez P, Al-Khami AA, et al. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci (Lond). 2015;129:951\u201362.","journal-title":"Clin Sci (Lond)"},{"key":"3623_CR13","first-page":"175","volume":"21","author":"L Han","year":"2024","unstructured":"Han L, Chen Y, Huang N, Zhou X, Lv Y, Li H, et al. Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression. Cancer Biol Med. 2024;21:175\u201392.","journal-title":"Cancer Biol Med"},{"key":"3623_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF03402154","volume":"8","author":"G Hask\u00f3","year":"2002","unstructured":"Hask\u00f3 G, Mabley JG, N\u00e9meth ZH, Pacher P, Deitch EA, Szab\u00f3 C. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol Med. 2002;8:283\u20139.","journal-title":"Mol Med"},{"key":"3623_CR15","doi-asserted-by":"publisher","first-page":"1743253","DOI":"10.1155\/2018\/1743253","volume":"2018","author":"EM Horv\u00e1th","year":"2018","unstructured":"Horv\u00e1th EM, Magenheim R, B\u00e9res NJ, Benk\u0151 R, P\u00e9k T, Tab\u00e1k \u00c1G, et al. Oxidative-nitrative stress and poly(ADP-ribose) polymerase activation 3 years after pregnancy. Oxid Med Cell Longev. 2018;2018:1743253.","journal-title":"Oxid Med Cell Longev"},{"key":"3623_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-6993-7_2","volume":"1608","author":"EM Horvath","year":"2017","unstructured":"Horvath EM, Zsengell\u00e9r ZK, Szabo C. Quantification of PARP activity in human tissues: ex vivo assays in blood cells and immunohistochemistry in human biopsies. Methods Mol Biol. 2017;1608:19\u201326.","journal-title":"Methods Mol Biol"},{"key":"3623_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-0039-1683996","volume":"40","author":"LA Huppert","year":"2019","unstructured":"Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2019;40:31\u20139.","journal-title":"Semin Respir Crit Care Med"},{"key":"3623_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"3623_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11010-014-2271-4","volume":"400","author":"K Kapoor","year":"2015","unstructured":"Kapoor K, Singla E, Sahu B, Naura AS. PARP inhibitor olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. Mol Cell Biochem. 2015;400:153\u201362.","journal-title":"Mol Cell Biochem"},{"key":"3623_CR20","doi-asserted-by":"publisher","unstructured":"Kieronska-Rudek A, Zuhra K, Ascen\u00e7\u00e3o K, Chlopicki S, Szabo C. The PARP inhibitor olaparib promotes senescence in murine macrophages. Geroscience. 2025. https:\/\/doi.org\/10.1007\/s11357-025-01679-6.","DOI":"10.1007\/s11357-025-01679-6"},{"key":"3623_CR21","doi-asserted-by":"publisher","first-page":"662034","DOI":"10.3389\/fneur.2021.662034","volume":"12","author":"RC Koehler","year":"2021","unstructured":"Koehler RC, Dawson VL, Dawson TM. Targeting parthanatos in ischemic stroke. Front Neurol. 2021;12:662034.","journal-title":"Front Neurol"},{"key":"3623_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bph.13983","volume":"175","author":"S Korkmaz-Ic\u00f6z","year":"2018","unstructured":"Korkmaz-Ic\u00f6z S, Szczesny B, Marcatti M, Li S, Ruppert M, Lasitschka F, et al. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats. Br J Pharmacol. 2018;175:246\u201361.","journal-title":"Br J Pharmacol"},{"key":"3623_CR23","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","volume":"27","author":"S Kummar","year":"2009","unstructured":"Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27:2705\u201311.","journal-title":"J Clin Oncol"},{"key":"3623_CR24","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3390\/antiox12112016","volume":"12","author":"EY Lim","year":"2023","unstructured":"Lim EY, Lee SY, Shin HS, Kim GD. Reactive oxygen species and strategies for antioxidant intervention in acute respiratory distress syndrome. Antioxidants. 2023;12:2016.","journal-title":"Antioxidants"},{"key":"3623_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ab.2008.07.007","volume":"381","author":"X Liu","year":"2008","unstructured":"Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, et al. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008;381:240\u20137.","journal-title":"Anal Biochem"},{"key":"3623_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10096-020-04020-5","volume":"40","author":"W Liu","year":"2021","unstructured":"Liu W, Ren X, Wang Q, Zhang Y, Du J. Pharmacological inhibition of poly(ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice. Eur J Clin Microbiol Infect Dis. 2021;40:159\u201367.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3623_CR27","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3390\/cells11233789","volume":"11","author":"V Martins","year":"2022","unstructured":"Martins V, Santos SS, Rodrigues LOCP, Salomao R, Liaudet L, Szabo C. Efficacy of clinically used PARP inhibitors in a murine model of acute lung injury. Cells. 2022;11:3789.","journal-title":"Cells"},{"key":"3623_CR28","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1074\/jbc.RA120.014479","volume":"296","author":"M Mashimo","year":"2021","unstructured":"Mashimo M, Onishi M, Uno A, Tanimichi A, Nobeyama A, Mori M, et al. The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis. J Biol Chem. 2021;296:100046.","journal-title":"J Biol Chem"},{"key":"3623_CR29","doi-asserted-by":"publisher","first-page":"602963","DOI":"10.3389\/fimmu.2021.602963","volume":"12","author":"E McKenna","year":"2021","unstructured":"McKenna E, Mhaonaigh AU, Wubben R, Dwivedi A, Hurley T, Kelly LA, et al. Neutrophils: need for standardized nomenclature. Front Immunol. 2021;12:602963.","journal-title":"Front Immunol"},{"key":"3623_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/cancers14030687","volume":"14","author":"M Mekhaeil","year":"2022","unstructured":"Mekhaeil M, Dev KK, Conroy MJ. Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases. Cancers (Basel). 2022;14:687.","journal-title":"Cancers (Basel)"},{"key":"3623_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","volume":"66","author":"P Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay P, Horv\u00e1th B, Rajesh M, Varga ZV, Gariani K, Ryu D, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol. 2017;66:589\u2013600.","journal-title":"J Hepatol"},{"key":"3623_CR32","doi-asserted-by":"publisher","first-page":"e0295837","DOI":"10.1371\/journal.pone.0295837","volume":"19","author":"K Mustafa","year":"2024","unstructured":"Mustafa K, Han Y, He D, Wang Y, Niu N, Jose PA, et al. Poly(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-\u03baB in THP-1 monocytes. PLoS ONE. 2024;19:e0295837.","journal-title":"PLoS ONE"},{"key":"3623_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000510269","volume":"13","author":"Y Nie","year":"2021","unstructured":"Nie Y, Nirujogi TS, Ranjan R, Reader BF, Chung S, Ballinger MN, et al. PolyADP-ribosylation of NFATc3 and NF-kappaB transcription factors modulate macrophage inflammatory gene expression in LPS-induced acute lung injury. J Innate Immun. 2021;13:83\u201393.","journal-title":"J Innate Immun"},{"key":"3623_CR34","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1093\/emboj\/18.16.4446","volume":"18","author":"FJ Oliver","year":"1999","unstructured":"Oliver FJ, de M\u00e9nissier- Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999;18:4446\u201354.","journal-title":"EMBO J"},{"key":"3623_CR35","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1007\/s12035-021-02371-4","volume":"58","author":"LN Puentes","year":"2021","unstructured":"Puentes LN, Lengyel-Zhand Z, Reilly SW, Mach RH. Evaluation of a low-toxicity PARP inhibitor as a neuroprotective agent for Parkinson\u2019s disease. Mol Neurobiol. 2021;58:3641\u201352.","journal-title":"Mol Neurobiol"},{"key":"3623_CR36","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1177\/0961203311418790","volume":"20","author":"MJ Rapoport","year":"2011","unstructured":"Rapoport MJ, Bloch O, Amit-Vasina M, Yona E, Molad Y. Constitutive abnormal expression of RasGRP-1 isoforms and low expression of PARP-1 in patients with systemic lupus erythematosus. Lupus. 2011;20:1501\u20139.","journal-title":"Lupus"},{"key":"3623_CR37","doi-asserted-by":"publisher","first-page":"173091","DOI":"10.1016\/j.ejphar.2020.173091","volume":"877","author":"B Sahu","year":"2020","unstructured":"Sahu B, Narota A, Naura AS. Pharmacological inhibition of poly(ADP-ribose) polymerase by olaparib prevents acute lung injury-associated cognitive deficits potentially through suppression of inflammatory response. Eur J Pharmacol. 2020;877:173091.","journal-title":"Eur J Pharmacol"},{"key":"3623_CR38","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/biom12060788","volume":"12","author":"SS Santos","year":"2022","unstructured":"Santos SS, Brunialti MKC, Rodrigues LOCP, Liberatore AMA, Koh IHJ, Martins V, et al. Effects of the PARP inhibitor olaparib on the response of human peripheral blood leukocytes to bacterial challenge or oxidative stress. Biomolecules. 2022;12:788.","journal-title":"Biomolecules"},{"key":"3623_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/SHK.0000000000001820","volume":"56","author":"SS Santos","year":"2021","unstructured":"Santos SS, Brunialti MKC, Soriano FG, Szabo C, Salom\u00e3o R. Repurposing of clinically approved poly-(ADP-ribose) polymerase inhibitors for the therapy of sepsis. Shock. 2021;56:901\u20139.","journal-title":"Shock"},{"key":"3623_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1023\/A:1016119328968","volume":"7","author":"C Soldani","year":"2002","unstructured":"Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7:321\u20138.","journal-title":"Apoptosis"},{"key":"3623_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1165\/rcmb.2020-0188TR","volume":"63","author":"C Szabo","year":"2020","unstructured":"Szabo C, Martins V, Liaudet L. Poly(ADP-ribose) polymerase inhibition in acute lung injury: a reemerging concept. Am J Respir Cell Mol Biol. 2020;63:571\u201390.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3623_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMra1608077","volume":"377","author":"BT Thompson","year":"2017","unstructured":"Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377:562\u201372.","journal-title":"N Engl J Med"},{"key":"3623_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2119\/2006-00055.Toth-Zsamboki","volume":"12","author":"E T\u00f3th-Zs\u00e1mboki","year":"2006","unstructured":"T\u00f3th-Zs\u00e1mboki E, Horv\u00e1th E, Vargova K, Pankotai E, Murthy K, Zsengell\u00e9r Z, et al. Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med. 2006;12:221\u20138.","journal-title":"Mol Med"},{"key":"3623_CR44","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0006-2952(03)00077-7","volume":"65","author":"B Veres","year":"2003","unstructured":"Veres B, Gallyas F Jr., Varbiro G, Berente Z, Osz E, Szekeres G, et al. Decrease of the inflammatory response and induction of the Akt\/protein kinase B pathway by poly(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol. 2003;65:1373\u201382.","journal-title":"Biochem Pharmacol"},{"key":"3623_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/pr.54.3.375","volume":"54","author":"L Vir\u00e1g","year":"2002","unstructured":"Vir\u00e1g L, Szab\u00f3 C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375\u2013429.","journal-title":"Pharmacol Rev"},{"key":"3623_CR46","doi-asserted-by":"publisher","first-page":"9483","DOI":"10.1038\/s41598-017-10307-z","volume":"7","author":"E Wi\u015bnik","year":"2017","unstructured":"Wi\u015bnik E, P\u0142oszaj T, Robaszkiewicz A. Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes. Sci Rep. 2017;7:9483.","journal-title":"Sci Rep"},{"key":"3623_CR47","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.nbd.2023.106314","volume":"187","author":"X Xu","year":"2023","unstructured":"Xu X, Sun B, Zhao C. Poly(ADP-ribose) polymerase 1 and parthanatos in neurological diseases: from pathogenesis to therapeutic opportunities. Neurobiol Dis. 2023;187:106314.","journal-title":"Neurobiol Dis"},{"key":"3623_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bj.2020.09.001","volume":"44","author":"SC Yang","year":"2021","unstructured":"Yang SC, Tsai YF, Pan YL, Hwang TL. Understanding the role of neutrophils in acute respiratory distress syndrome. Biomed J. 2021;44:439\u201346.","journal-title":"Biomed J"},{"key":"3623_CR49","doi-asserted-by":"publisher","first-page":"103243","DOI":"10.1016\/j.redox.2024.103243","volume":"75","author":"M Zampieri","year":"2024","unstructured":"Zampieri M, Karpach K, Salerno G, Raguzzini A, Barchetta I, Cimini FA, et al. PAR level mediates the link between ROS and inflammatory response in patients with type 2 diabetes mellitus. Redox Biol. 2024;75:103243.","journal-title":"Redox Biol"},{"key":"3623_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s42255-025-01225-w","volume":"7","author":"K Zuhra","year":"2025","unstructured":"Zuhra K, Petrosino M, Janickova L, Petric J, Ascen\u00e7\u00e3o K, Vignane T, et al. Regulation of mammalian cellular metabolism by endogenous cyanide production. Nat Metab. 2025;7:531\u201355.","journal-title":"Nat Metab"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03623-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:12:37Z","timestamp":1781640757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03623-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03623-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Vaud Canton's Human Research Ethical Commission (CER-VD; protocol number 2022\u201301193). All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}